11 October 2022: Original Paper
Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies
Shu Fang 12ABCDEF* , Nan Wang 23ABCF* , Lili Wang 2ABCD* , Jishan Du 23BCF , Jingjing Yang 23BCF , Yanan Wen 23BCF , Yan Wei 23BCF , Kun Qian 12BCD , Hao Wang 23ABF , Yifan Jiao 23BCF , Chunji Gao 12ACEG* , Liping Dou 2ABDEG*DOI: 10.12659/AOT.937356
Ann Transplant 2022; 27:e937356
Table 1 Clinical characteristics of 85 patients.
| Characteristics | ATG group | Non-ATG group | p value |
|---|---|---|---|
| No. of patients | 40 | 45 | |
| Patient’s age, y, median (range) | 39 (18–60) | 37 (12–63) | 0.567 |
| Gender, No. (%) | 0.411 | ||
| Male | 24 (60.0) | 23 (51.1) | |
| Female | 16 (40.0) | 22 (48.9) | |
| Time interval between diagnosis and HSCT, d, median (range) | 0.160 | ||
| 17 (42.5) | 26 (57.8) | ||
| ≥6 m | 23 (57.5) | 19 (42.2) | |
| Diagnosis, No. (%) | 0.013 | ||
| AML/MDS | 23 (57.5) | 37 (82.2) | |
| ALL | 17 (42.5) | 8 (17.8) | |
| Disease status at transplantation, No. (%) | 0.136 | ||
| CR | |||
| MRD− | 24 (60.0) | 16 (35.6) | |
| MRD+ | 11 (27.5) | 17 (37.8) | |
| Untreated MDS-AML | 3 (7.5) | 8 (17.8) | |
| Refractory/Relapsed | 2 (5.0) | 4 (8.9) | |
| Cytogenetic risk, No. (%) | 0.116 | ||
| Favorable | 3 (7.5) | 6 (13.3) | |
| Intermediate | 21 (52.5) | 30 (66.7) | |
| Poor | 16 (40.0) | 9 (20.0) | |
| Disease Risk Index, No. (%) | 0.124 | ||
| Low/intermediate | 24 (60.0) | 34 (75.6) | |
| High/very high | 16 (40.0) | 11 (24.4) | |
| Conditioning regimen, No. (%) | 0.066 | ||
| Bu/Cy | 37 (92.5) | 42 (93.3) | |
| TBI/Cy | 3 (7.5) | 0 (0.0) | |
| FB | 0 (0.0) | 1 (2.2) | |
| FLAG/Bu | 0 (0.0) | 2 (4.4) | |
| Donor’s age, y, median (range) | 38.5 (12.0–59.0) | 36.0 (11.0–58.0) | 0.546 |
| Donor-recipient ABO match, No. (%) | 0.145 | ||
| Match | 22 (55.0) | 31 (68.9) | |
| Major mismatch | 5 (12.5) | 8 (17.8) | |
| Minor mismatch | 12 (30.0) | 6 (13.3) | |
| Bidirectional mismatch | 1 (2.5) | 0 (0.0) | |
| Donor-recipient gender match, No. (%) | 0.458 | ||
| Male to male | 8 (20.0) | 12 (26.7) | |
| Female to female | 9 (22.5) | 14 (31.1) | |
| Male to female | 7 (17.5) | 8 (17.8) | |
| Female to male | 16 (40.0) | 11 (24.4) | |
| Graft, median (range) | |||
| MNCs, ×10/kg, | 11.65 (6.17–25.60) | 8.99 (4.75–18.23) | |
| CD34 cells, ×10/kg | 4.65 (2.25–9.17) | 3.21 (1.96–9.26) | 0.001 |
| ATG – anti-thymocyte globulin; HSCT – hematopoietic stem cell transplantation; MDS – myelodysplastic syndrome; AML – acute myeloid leukemia; ALL – acute lymphoblastic leukemia; CR – complete remission; MRD – minimal residual disease; MNCs – mononuclear cells; no. – number of patients. | |||